AMES, Iowa, June 28 /PRNewswire-FirstCall/ -- BioForce Nanosciences
(OTC Bulletin Board: BFNH), which develops and markets commercial products
for nanotechnology applications, has announced that Dr. Guenter H. Jaensch
and Kerry Frey, BioForce's chief operating officer, have joined the
Jaensch is a former executive at Siemens, where he held positions both
in Europe and the US. During his more than 25 years with Siemens, he served
as president of Siemens Communications, Inc., chairman & president of
Siemens Corporate Research and Support, Inc., and chairman and CEO of
Siemens Pacesetter, Inc. When St. Jude Medical, Inc., acquired Siemens
Pacesetter in 1994, Jaensch was key to the transition process and stayed as
chairman and CEO of Pacesetter, Inc., a St. Jude Medical Company, until
1995. Since 1997, Jaensch has been a director of MRV Communications, Inc.,
a leading company in the fiber optic technology business; since 2002 he has
served as chairman of the Board of Biophan Technologies, Inc.
"There is a great deal of noise about nanotechnology in the market but
so far only very few practical applications," Jaensch said. "With its
NanoArrayer System, BioForce offers exciting and immediately usable tools
for the growing field of bionanotechnology."
Frey joined BioForce earlier this year with more than 30 years of
broad-based management and operational experience in the medical device,
pharmaceutical and healthcare industries. Over the course of his career, he
has developed and implemented innovative and profitable new products,
programs and services with such companies as Medisys Technologies and
Johnson and Johnson.
"I am excited about working with the people at BioForce as we bring
innovative new products to the marketplace and continue to position the
company in the forefront of the bionanotechnology industry," Frey said.
"Both Guenter and Kerry bring a wealth of experience to BioForce," said
Dr. Eric Henderson, founder and CEO. "They will be invaluable additions as
we continue to build on our technology and look to enhance shareholder
value as we grow our company."
About BioForce Nanosciences, Inc.
BioForce Nanosciences provides innovative and practical commercial
products for applications in nanotechnology, with more than a decade of
invention, research and development of patented and patent-pending
products. The core technology is the NanoArrayer(TM) System, a proprietary
platform for precision printing and surface patterning. The NanoArrayer(TM)
System includes a consumable line of print cartridges and chip surfaces.
This system enables new and important applications in the biomedical and
life sciences markets. BioForce continues to target inventions that further
expand the reach of its proprietary technology. The ViriChip(TM) System, a
patented diagnostic device for rapid detection and identification of
multiple viruses on a single chip, is an example of the Company's
technology expansion program.
BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) company,
brings inventions to the marketplace that complement existing innovations,
licensing and acquisitions. BioForce is a wholly owned subsidiary of
BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). For
more information, visit http://www.bioforcenano.com or contact BioForce at
firstname.lastname@example.org or 515-233-8333.
SOURCE BioForce Nanosciences